GlassScriptPhysician profile
Jason Austin
NPI 1013963818
$14,760.55
in general payments reported to CMS, 2019-2025
61 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $1,142 · 2021: $2,657 · 2022: $3,097 · 2023: $2,652 · 2024: $2,366 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,277 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,276.51 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,767.83 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $1,600.17 | 2019-2024 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $1,533.78 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,333.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Pfizer INC. | $1,323.54 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $837.59 | 2021-2024 | Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $546.19 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $490.72 | 2019-2025 | |
| Novo Nordisk INC | $405.26 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Nestle Healthcare Nutrition INC. | $309.23 | 2021-2023 | |
| Astellas Pharma US INC | $299.05 | 2019-2023 | Veozah |
| Abbott Laboratories | $298.46 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $277.48 | 2021-2024 | Repatha, Otezla, Tezspire |
| Lundbeck LLC | $254.22 | 2020-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $251.43 | 2019-2023 | Airduo Digihaler |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.